The immuno-oncology drug ‘Imfinzi’ added an indication in Korea and can be used in combination with ‘Imjudo’ in Korea.

According to industry sources, AstraZeneca received approval for the combined use of Imfinzi+Imjudo from the Ministry of Food and Drug Safety on June 30th, immediately after receiving approval for its CTLA-4 inhibiting cancer immunotherapy Imjudo (tremelimumab) in Korea.

The immunotherapy combo will first target liver cancer, as the combination was approved as a first-line treatment for adult patients with advanced or unresectable hepatocellular carcinoma (liver cancer).

More specifically, the approved STRIDE regimen (Single Tremelimumab Regular Interv